0.2-0.4T静磁场对肿瘤细胞生长和黏附功能的影响

目的:研究0.2-0.4 T中强静磁场对肿瘤细胞生长和黏附的影响.方法:用0.2-0.4 T静磁场对SMMC-7721、HepG2和MCF-7细胞曝磁处理后,用噻唑蓝(MTT)法检测中强磁场对SMMC-7721、HepG2和MCF-7细胞生长增殖的影响.通过结晶紫染色检测细胞对FN黏附能力的变化,并应用流式细胞技术检测中强磁场对肿瘤细胞周期的影响.结果:中强磁场影响SMMC-7721、HepG2和MCF-7细胞的生长和黏附功能.中强磁场对不同的肿瘤细胞有不同的效应,对SMMC-7721的生长没有明显的影响,但降低SMMC-7721黏附能力(1.847±0.342 vs 1.094±0.33,P=0.012).与对照组相比SMMC-7721细胞周期的G2/M的百分比降低(12.05%±1.14% vs3.74%±0.87%,P=0.018).而对于MCF-7细胞,中强磁场促进细胞的增殖,增强细胞对FN的黏附能力(1.094±0.076 vs 2.177±0.474,P=0.017),使其G2/M的百分比降低(4.42%±1.23% vs 12.04%±1.65%,P=0.004).HepG2细胞在中强磁场中,细胞的增殖受到抑制,对FN的黏附能力没有明显的变化(0.305±0.076vs 0.394±0.089,P=0.467),但G2/M的百分比有所升高(1.90%+0.79% vs 0.24%±0.15%,P=0.0461.结论:0.2-0.4 T中强静磁场对不同的肿瘤细胞有不同的影响.     

原花青素对人肝癌细胞SMMC-7721增殖及凋亡的作用

目的探讨葡萄籽提取物原花青素（PA）对人肝癌细胞SMMC-7721增殖和凋亡的影响。方法取对数生长期人肝癌细胞SMMC-7721,分别加人20、40、60mg／L的PA培养24h后,采用MTI＂法检测细胞增殖抑制率、流式细胞仪分析细胞凋亡率,并测定细胞内超氧化物歧化酶（SOD）活力、丙二醛（MDA）和活性氧簇（ROS）等指标。结果20、40、60mg／L的PA对人肝癌细胞SMMC-7721的增殖抑制率分别为（22．7±1．8）％、（38．6±1。9）％、（47．6±2．5）％,细胞凋亡率分别为（19．7±5．1）％、（29．7±2．9）％、（48．5±4．5）％,两者均随PA浓度的升高而增高（P均〈0．01）;与对照组比较,各剂量组人肝癌细胞SMMC-7721中MDA、ROS水平逐渐下降（P〈0．05）;SOD活力逐渐上升（P〈0．05）。结论PA在体外可呈浓度依赖性抑制人肝癌细胞SMMC-7721的增殖及凋亡,其作用机制可能与清除ROS、提高SOD的活性、降低脂质过氧化反应等有关。     

复方苦参注射液对人肝癌SMMC－7721肿瘤细胞作用的实验研究

选用人肝癌SMMC－7721肿瘤细胞,分别采用MTT法、流式细胞仪检测复方苦参注射液对人肝癌SMMC-7721肿瘤细胞体外增殖抑制率、细胞周期、凋亡率的影响。提示18．75～300μl／ml的复方苦参注射液在作用48h时对人肝癌SMMC-7721肿瘤细胞的增殖抑制率在12．3％～82．5％,随着浓度的增加,细胞增殖抑制率逐渐上升,呈剂量依赖性。复方苦参注射液终浓度75μl／ml作用后的人肝癌SMMC-7721肿瘤细胞G0～G1期明显增高,S期、G2～M期的细胞比例明显减少,凋亡率（58．21％）明显高于对照组（4．17％）。提示复方苦参注射液对人肝癌SMMC-7721细胞具有明显的增殖抑制作用,并影响细胞周期,促进其凋亡。     

肝细胞生长因子对肝癌细胞系SMMC-7721失巢凋亡的影响

目的:探讨HGF对SMMC-7721失巢凋亡的影响以及P13K在该过程中的作用.方法:悬浮培养SMMC-772l,建立失巢凋亡模型.应用TUNEL染色观察凋亡率.分别悬浮培养SMMC-7721、HGF处理后SMMC-721及LY294002预处理后的HGF处理细胞,用台盼蓝染色观察细胞失巢凋亡后存活率,用MTT检测细胞的增殖能力的变化,流式细胞仪检测失巢凋亡细胞的早、晚期凋亡率,Hoechst染色观察不同处理细胞的凋亡情况.应用免疫印迹技术检测失巢凋亡后Akt、p-Akt、FAK、p-FAK的表达.结果:TUNEL染色显示,悬浮培养的SMMC-7721失巢凋亡率远大于贴壁培养的SMMC-7721(21.72%±6.85% vs 66.67%±7.66%,P<0.05);台盼蓝染色显示,HGF处理后的SMMC-7721存活率明显高于悬浮培养细胞(P<0.05),而HGF不能提高经LY294002预处理后细胞的存活率:MTT实验显示HGF处理细胞A值明显大于悬浮培养细胞(P<0.05),LY294002预处理细胞与悬浮培养细胞相似.流式细胞仪和Hoechst 33258染色均显示HGF处理后细胞的失巢凋亡明显低于悬浮培养细胞(P<0.05),而经LY294002处理后细胞的失巢凋亡率明显升高.蛋白印迹结果显示HGF处理后细胞Akt、FAK、p-Akt、p-FAK的表达均升高,而经LY294002预处理后,其表达与悬浮培养SMMC-7721一致.结论:在肝细胞癌SMMC-7721失巢凋亡过程中,HGF通过活化Akt和FAK来增强细胞的抗失巢凋亡能力,该作用受P13K的调节.     

熊果酸诱导人肝癌SMMC-7721细胞凋亡的研究

目的：观察熊果酸（UA）对人肝癌SMMC-7721细胞的增殖抑制及诱导其凋亡作用。方法：MTT法检测5、10、20、30、40、50μmol/L UA对SMMC-7721细胞生长的抑制作用,吖啶橙（AO）荧光染色、电镜和流式细胞仪检测细胞凋亡。结果：UA能显著抑制SMMC-7721细胞的增殖,其作用呈剂量依赖性。35.2μmol/L UA作用SMMC-7721细胞48小时后AO染色,荧光显微镜下可见细胞出现体积缩小,核碎裂,染色质凝集等凋亡形态改变;电镜下SMMC-7721细胞出现明显的细胞凋亡的形态学改变,细胞核染色质出现边聚和中聚,细胞内部分线粒体肿胀;SMMC-7721细胞凋亡率为（67.91±5.24）%,与对照组（2.95±0.56）%比较差异有显著性意义（P〈0.05）。结论：UA通过诱导SMMC-7721细胞凋亡抑制其生长。     

Egr-1基因表达及其在射线诱导的肝癌细胞凋亡中的作用

目的:研究Egr-1基因的表达在放射诱导的细胞凋亡中的作用．方法:选择肝癌细胞系HepG2,SMMC-7721和正常肝细胞系HL-7702培养;培养细胞接受4Gy X射线照射;收获受照前和受照后1,2,4, 6,12和24 h的细胞,采用荧光定量PCR(FQ- PCR)检测0,1,2和4 h Egr-1基因的表达,采用流式细胞术(FCM)检测0,6,12和24 h细胞周期和细胞凋亡．结果:随HepG2,SMMC-7721和HL-7702在4GY X射线照射后1 h即诱导了Egr-1基因表达增高,4 h均未达峰值,分别为ΔEgrHepG2(12．9629±1．0649)、ΔEgr7702(0．0096±0．0008)和ΔEgr7721(0．0017±0．0003),HepG2显著高于HL-7702和SMMC-7721(P<0．01)．照射后6 h射线诱导的3株细胞凋亡均不明显,但在12 h均诱导了明显的细胞凋亡,而且HepG2(41．16％)和HL-7702(27．45％)已达峰值; SMMC-7721诱导的细胞凋亡水平较低,24 h仅为24．94％,且未达峰值．在射线诱导的细胞周期变化中,HepG2和SMMC-7721 S期的变化与细胞凋亡变化在6-12 h走势相反．结论:在HepG2,SMMC-7721和HL-7702细胞中,射线通过诱导Egr-1基因表达而诱导了细胞周期和细胞凋亡的变化;射线诱导的Egr-1基因表达水平可能与射线诱导的细胞凋亡成正相关;S期肿瘤细胞可能易发生射线诱导的细胞凋亡．     

羟基喜树碱对人肝癌细胞增殖影响及凋亡诱导

目的 探讨羟基喜树碱对人肝癌细胞株SMMC-7721增殖的影响及其诱导凋亡的作用。方法 以不同浓度的羟基喜树碱在体外作用于人肝癌细胞株SMMC-7721,采用MTT法检测细胞增殖;化学荧光法检测Bcl-2的细胞表达;电镜观察、流式细胞仪与原位末端标记方法检测细胞凋亡情况。结果 与空白对照组比较,羟基喜树碱浓度在3.125μg/mL～100μg/mL组,对肿瘤细胞的增殖抑制率显著增高(P<0.01);在0.05mg/mL组出现细胞早期凋亡现象,Bcl-2表达明显减少;在0.1mg/mL组形成凋亡小体;细胞凋亡比例随羟基喜树碱浓度增加而增高。结论 羟基喜树碱在体外可抑制人肝癌细胞株SMMC-7721增殖,其作用机制可能系通过抑制Bcl-2表达诱导细胞凋亡。     

五倍子酸诱导肝癌SMMC-7721细胞凋亡

目的 探讨五倍子酸对人肝癌SMMC-7721细胞增殖和凋亡的影响.方法 采用MTT法检测五倍子酸对SMMC-7721细胞的增殖抑制作用,瑞士-吉姆萨染色观察细胞形态变化,流式细胞仪检测细胞凋亡百分率.结果 五倍子酸能抑制SMMC-7721细胞的增殖,其作用呈明显剂量依赖性.五倍子酸可诱导SMMC-7721细胞凋亡,与对照组比较差异有统计学意义.结论 五倍子酸可抑制SMMC-7721细胞的增殖,并诱导其凋亡.     

黄芩苷对肝癌细胞SMMC-7721 JAK-STAT信号通路STAT3的影响

目的:探讨黄芩苷对肝癌细胞SMMC-7721JAK-STAT信号通路STAT3的影响.方法:将肝癌细胞SMMC-7721分为4组:对照组、黄芩苷组、AG490组、黄芩苷+AG490组.应用RT-PCR法检测各组肝癌细胞SMMC-7721中STAT3mRNA表达,Westernblot法检测肝癌细胞SMMC-7721中STAT3、P-STAT3蛋白表达.结果:黄芩苷可以下调肝癌细胞SMMC-7721STAT3mRNA表达,与对照组比较明显下降(0.505±0.111vs0.697±0.145,P<0.05);并可以降低STAT3蛋白的表达量(0.879±0.012vs1.087±0.015,P<0.05);还可以抑制STAT3向活化形式P-STAT3转化,与对照组比较P-STAT3表达明显下降(0.983±0.085vs1.103±0.074,P<0.05),而与AG490联合应用后P-STAT3蛋白表达量较单用黄芩苷下降明显(0.756±0.103vs0.983±0.085,P<0.05).结论:黄芩苷能下调STAT3mRNA表达水平,降低STAT3蛋白表达,还可以抑制STAT3向活化形式P-STAT3转化,...     

survivin反义寡核苷酸对SMMC-7721细胞增殖和凋亡的影响

目的 观察survivin反义寡核苷酸(ASODN)对人肝癌细胞株SMMC-7721增殖和凋亡的影响.方法 人工合成survivin基因ASODN和正义ODN(SODN),并行硫代磷酸化修饰,通过脂质体途径转染SMMC-7721;分别用RT-PCR和Western blot检测survivin mRNA和蛋白表达;用MTT法检测ASODN对SMMC-7721增殖的影响;流式细胞仪检测细胞周期变化及细胞凋亡率;倒置显微镜观察细胞形态变化.结果 SMMC-7721可强表达survivin mRNA和蛋白;ASODN呈浓度依赖性抑制survivin mRNA和蛋白表达及SMMC-7721增殖,诱导细胞凋亡,使细胞阻滞于G2/M期.SODN对survivin mRNA和蛋白及SMMC-7721的增殖、细胞周期无明显抑制作用.结论 脂质体介导转染survivin ASODN可抑制细胞增殖、使细胞阻滞于G2/M期,从而促进细胞凋亡.     

Conjugated Linoleic Acid-Induced Toxic Hepatitis: First Case Report

A 46-year-old female patient was referred to our department with presenting symptoms of asthenia, jaundice, and pruritus. There was no medical history or clinical evidence of viral hepatitis, autoimmune hepatitis, hemochromatosis, or Wilson’s disease. The patient revealed that 14 days prior to admission she had begun self-medicating with conjugated linoleic acid (CLA) to reduce body fat, leading to the suspicion of CLA hepatotoxicity, which was subsequently confirmed by a liver biopsy. After the patient ceased to ingest CLA, liver enzymes levels normalized. To the best of our knowledge, this is the first report of hepatotoxicity due to CLA ingestion.     

Conjugated and non-conjugated octadecaenoic acids affect differently intestinal acyl coenzyme A: cholesterol acyltransferase activity

We investigated the relative hypocholesterolemic activity of linoleic acid (LA), conjugated linoleic acid (CLA), -linolenic acid (LN) and conjugated linolenic acid (CLN) in hamsters. Five groups of hamsters (n = 10 each) were fed either the control diet or one of the four fatty acids-supplemented diets for 6 weeks. Results demonstrated that the four octadecaenoic acids decreased plasma cholesterol differently, with CLA being the most effective. Western blotting and RT-PCR analysis demonstrated that the four octadecaenoic acids had no effect on sterol regulatory element binding protein-2 (SREBP-2), liver X receptor (LXR), 3-hydroxy-3-methylglutary-CoA reductase (HMGR), LDL receptor (LDLR), and cholesterol-7-hydroxylase (CYP7A1). However, the four octadecaenoic acids increased the excretion of fecal neutral sterols with CLA being most effective followed by LN, LA and CLN, suggesting they all differentially affect cholesterol absorption. Dietary CLA was associated with the least intestinal acyl coenzyme A: cholesterol acyltransferase (ACAT) activity followed by LN, LA and CLN in a decreasing trend. Since esterification of cholesterol is catalyzed by intestinal ACAT, and is a rate-limiting step in cholesterol absorption, it was concluded that the varying effects of CLA, LN, LA and CLN on blood cholesterol were mediated, at least in part, by their inhibition on intestinal ACAT activity.     

铜绿假单胞菌胞外粘液多糖结合菌苗的实验研究

目的 探讨绿脓杆菌胞外粘液多糖（MEP）制备的结合菌苗的免疫效果。方法 将绿脓杆菌MEP与B群脑膜炎球菌外膜蛋白复合物（OMPC）交联制成MEP－OMPC结合菌苗。免疫小鼠后，以ELISA法检测血清中抗MEP（IgG)抗体水平，并观察其对细菌腹腔攻击的保护作用。结果 以MEP－OMPC免疫小鼠后，所产生的抗MEP(IgG)抗体水平明显高于单纯MEP免疫组和BPS对照组，并能有效地预防绿脓杆菌的全身感染。结论 绿脓杆菌MEP－OMPC结合菌苗较单纯MEP具有更强免疫原性，能有效地诱生调理性抗体和预防绿脓杆菌全身感染。     

Effect of oral gold salt therapy on bile acid absorption in rheumatoid arthritis patients

Summary Several studies pointed out an altered stool pattern as the most common side effect of auranofin therapy. The major mechanism in the aetiology of auranofin-induced impairment in bowel habit seems to be the inhibition of Na⁺/K⁺ A TPase in the gut. In vitro experiments proved that auranofin can affect active bile acid (BA) reabsorption in rat terminal ileum; this action, due to the ability of the drug to reduce Na⁺ pump activity by inhibiting Na⁺/K⁺ATPase, may make a significant contribution to the auranofininduced diarrhoea. The ability of auranof in to reduce the Na⁺ gradient necessary for active BA reabsorption, however, could cause a decrease of serum BA levels in patients taking auranofin before or without the development of an overt diarrhoea. We measured fasting and postprandial serum conjugated BA levels in 10 female rheumatoid arthritis patients before and after one month and two months' auranofin treatment. No patient developed diarrhoea during the chrysotherapy. When oral gold salt therapy was started, we observed a slight decrease in serum BA levels, but difference was not statistically significant. We can conclude that auranofin therapy does not cause BA malabsorption in patients who do not develop diarrhoea during the treatment.     

Biliary atresia and congenital disorders of the extrahepatic bile ducts

Biliary atresia (BA) and choledochal cysts are diseases of the intrahepatic and extrahepatic biliary tree. While their exact etiopathogeneses are not known, they should be treated promptly due to the potential for irreversible parenchymal liver disease. A diagnosis of BA may be easy or complicated, but should not be delayed. BA is always treated surgically, and performing the surgery before the age of 2 mo greatly increases its effectiveness and extends the time until the need for liver transplantation arises. While the more common types of choledochal cysts require surgical treatment, some can be treated with endoscopic retrograde cholangiopancreatography. Choledochal cysts may cause recurrent cholangitis and the potential for malignancy should not be ignored.     

甲硝唑栓联合结合雌激素软膏治疗老年性阴道炎的疗效分析

目的探讨甲硝唑栓与结合雌激素软膏联合治疗老年性阴道炎的疗效。方法选择该院2013-01~2015-04接诊的自愿接受该研究的老年性阴道炎患者180例,按照序号奇偶分为研究组和对照组各90例。对照组采取甲硝唑栓治疗,研究组给予甲硝唑栓与结合雌激素软膏治疗,随访半年以上,比较两组临床疗效。结果研究组总有效率为96.67%,明显高于对照组的76.67%,差异有统计学意义(P0.05);研究组随访半年复发率为16.67%,显著低于对照组的40.00%,差异有统计学意义(P0.05);两组治疗前血清促卵泡生成素(FSH)、雌二醇(E2)比较差异无统计学意义(P0.05),治疗后FSH明显升高、E2明显降低,与治疗前相比差异有统计学意义(P0.05),但治疗后研究组FSH更高、E2更低,差异有统计学意义(P0.05)。结论老年性阴道炎患者采取甲硝唑栓与结合雌激素软膏联合治疗,不仅可提高临床效果,而且可以显著改善FSH与E2水平,降低复发率,值得借鉴。     

The effect of conjugated equine oestrogen on diabetes incidence: the Women’s Health Initiative randomised trial

Aims/hypothesis Recent clinical trials have found that the combination of conjugated equine oestrogen (CEO) and medroxyprogesterone has a protective effect on the incidence of type 2 diabetes. To determine the effect of CEO alone on the incidence of diabetes mellitus in postmenopausal women, we analysed the results of the Women’s Health Initiative oestrogen-alone trial. Methods The Women’s Health Initiative is a randomised, double-masked trial comparing the effect of daily 0.625 mg CEO with placebo during 7.1 years of follow-up of 10,739 postmenopausal women who were aged 50–79 years and had previously had a hysterectomy. Diabetes incidence was ascertained by self-report of treatment with insulin or oral hypoglycaemic medication. Fasting glucose, insulin and lipoproteins were measured in an 8.6% random sample of study participants, at baseline and at 1, 3 and 6 years. Results The cumulative incidence of treated diabetes was 8.3% in the oestrogen-alone group and 9.3% in the placebo group (hazard ratio 0.88, 95% CI 0.77–1.01, p=0.072). During the first year of follow-up, a significant fall in insulin resistance (homeostasis model assessment of insulin resistance) in actively treated women compared with the control subjects (Year 1 baseline between-group difference −0.53) was seen. However, there was no difference in insulin resistance at the 3- or 6-year follow-up. Conclusions/interpretation Postmenopausal therapy with oestrogen alone may reduce the incidence of treated diabetes. The effect is smaller than that seen with oestrogen plus progestin. CEO should not, however, be used with the intention of preventing diabetes, as its well-described adverse effects preclude long-term use for primary prevention. Electronic Supplementary Material Supplementary material is available for this article at     

Prognostic implications of ischemia modified albumin in known cases of 86 elderly hypertensive South Asian aged 56–64 years – a hospital based study

ObjectiveTo study associated ischemia modified albumin in hypertensive participants and to compare the results with normotensive healthy controls.MethodsA total of 86 hypertensive patients and 86 age-sex matched normotensive healthy volunteers were selected for this study. The study was conducted for a period of 3 years from September 2007 to August 2010. Biochemical parameters and other parameters such as smoking habits, systolic and diastolic blood pressure and family history were recorded. Lipid profile, ischemia modified albumin, malondialdehyde and conjugated diene were measured by standard methods and results were compared between patients and controls.ResultsTotal cholesterol, triglycerides, low density lipoprotein cholesterol were significantly higher (P<0.001) in hypertensive subjects when compared to normotensive control. Also, significant differences were seen in high density lipoprotein cholesterol levels between both groups (P<0.001). The index of lipid per oxidation comprising both malondialdehyde and conjugated dienes were significantly higher in hypertensive compared to normotensive controls. Ischemia modified albumin levels were significantly increased among hypertensive compared to normotensive controls (P<0.001).ConclusionsHypertensive patients have increased oxidative stress and are accompanied with rise in ischemia modified albumin. Ischemia modified albumin could be incorporated as a diagnostic test parameter in hypertensive to avoid the future acute coronary complications.     

Conjugated linoleic acid (CLA): is it time to supplement asthma therapy?

The limitations and side effects of existing asthma therapies prompt interest in complementary and alternative therapies. Conjugated linoleic acids (CLA) are a family of natural fatty acids found primarily in beef and dairy products. These molecules have a variety of biological properties which suggest potential benefit in asthma, including effects on energy regulation, lipid metabolism, inflammation and immune function. Here we review the evidence for these effects from pre-clinical and clinical studies, their significance in the context of human asthma, and discuss the potential role for CLA supplementation in asthma management.